We are live on ! Find out more
SL

Siren LLC Portfolio holdings

AUM $3.61B
1-Year Est. Return 203.3%
This Fund
S&P 500
This Quarter Est. Return
-13.7%
1 Year Est. Return
+203.3%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.77B
AUM Growth
-$491M
Cap. Flow
+$34.8M
Cap. Flow %
1.96%
Top 10 Hldgs %
50.37%
Holding
141
New
23
Increased
28
Reduced
41
Closed
25

Top Buys

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$70.8M
2
IRON icon
Disc Medicine
IRON
+$59.6M
3
EWTX icon
Edgewise Therapeutics
EWTX
+$25.2M
4
DYN icon
Dyne Therapeutics
DYN
+$19.6M
5
SLNO
Soleno Therapeutics
SLNO
+$18.3M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$70.8M
2
SWTX
SpringWorks Therapeutics
SWTX
+$49.8M
3
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$38.9M
4
ONC
BeOne Medicines Ltd
ONC
+$36.2M
5
CYTK icon
Cytokinetics
CYTK
+$18.9M

Sector Composition

Rank Sector Weight
1 Healthcare 89.75%
2 Technology 5.2%
3 Communication Services 2.41%
4 Consumer Discretionary 1.21%
5 Real Estate 0.81%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IONS icon
126
Ionis Pharmaceuticals
IONS
$9.4B
– –
-250,000
Closed -$8.74M
IOVA icon
127
Iovance Biotherapeutics
IOVA
$2.87B
– –
-1,106,040
Closed -$8.18M
JANX icon
128
Janux Therapeutics
JANX
$967M
– –
-175,000
Closed -$9.37M
KURA icon
129
Kura Oncology
KURA
$850M
– –
-1,339,942
Closed -$11.7M
MDGL icon
130
Madrigal Pharmaceuticals
MDGL
$11.8B
– –
-125,942
Closed -$38.9M
META icon
131
Meta Platforms (Facebook)
META
$1.51T
– –
-1,000
Closed -$586K
MNDY icon
132
monday.com
MNDY
$3.94B
– –
-2,000
Closed -$471K
NU icon
133
Nu Holdings
NU
$66.9B
– –
-50,000
Closed -$518K
OVID icon
134
Ovid Therapeutics
OVID
$491M
– –
-2,850,000
Closed -$2.66M
PHAT icon
135
Phathom Pharmaceuticals
PHAT
$692M
– –
-460,753
Closed -$3.74M
RGNX icon
136
Regenxbio
RGNX
$708M
– –
-284,000
Closed -$2.2M
SE icon
137
Sea Limited
SE
$69.5B
– –
-25,000
Closed -$2.65M
SLRN
138
DELISTED
ACELYRIN
SLRN
– –
-1,729,665
Closed -$5.43M
SWTX
139
DELISTED
SpringWorks Therapeutics
SWTX
– –
-1,377,701
Closed -$49.8M
ACHL
140
DELISTED
Achilles Therapeutics
ACHL
– –
-755,375
Closed -$861K
OMGA
141
DELISTED
Omega Therapeutics, Inc. Common Stock
OMGA
– –
-1,323,530
Closed -$987K
2 3 4 5
6

Similar funds

SCM
Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return
ACM
Advent Capital Management New York $3.63B AUM 0.29% 1-Year Est. Return
GCM
Ghisallo Capital Management Boston, Massachusetts $3.63B AUM 30.51% 1-Year Est. Return
VI
Vestcor Inc Fredericton, New Brunswick, Canada $3.63B AUM 21.49% 1-Year Est. Return
BPS
BNDES Participacoes SA Rio De Janeiro, Brazil $3.58B AUM
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
WWA
WCG Wealth Advisors Las Vegas, Nevada $3.57B AUM 18.63% 1-Year Est. Return
OCM
One Capital Management Westlake Village, California $3.65B AUM 15.32% 1-Year Est. Return

Siren LLC's Q1 2025 Portfolio in Review

As of Q1 2025, Siren LLC held 141 positions worth $1.77B, down 22% from $2.26B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Siren LLC's Q1 2025 filing shows 23 new, 28 increased, 41 reduced and 25 closed positions. Its largest new stake was Blueprint Medicines: 726,167 shares worth $64.3M. The largest sale was argenx, an estimated $70.8M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 93% a quarter earlier, followed by Technology and Communication Services.

  • Siren LLC's largest Q1 2025 buy was Blueprint Medicines: 726,167 shares worth $64.3M.
  • Siren LLC added most to Edgewise Therapeutics in Q1 2025, an estimated $25.2M increase.
  • Siren LLC's biggest Q1 2025 reduction was BeOne Medicines Ltd, cutting an estimated $36.2M.
  • Siren LLC fully exited argenx in Q1 2025, selling an estimated $70.8M.
  • Siren LLC's ten largest holdings make up 50% of its $1.77B portfolio in Q1 2025.
  • Siren LLC opened 23 new positions and closed 25 in Q1 2025.
  • Siren LLC's portfolio value fell 22% quarter-over-quarter to $1.77B.

Based on Siren LLC's 13F filing for Q1 2025, filed 14 May 2025.